Gastrointestinal Pathogen Testing Market Report 2026

The gastrointestinal pathogen testing market size has grown steadily in recent years. It will grow from $4.23 billion in 2025 to $4.41 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to high prevalence of gastrointestinal infections, adoption of culture-based testing, hospital laboratory expansion, foodborne illness outbreaks, public health surveillance programs.

The gastrointestinal pathogen testing market size is expected to see steady growth in the next few years. It will grow to $5.06 billion in 2030 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to growth in syndromic testing panels, expansion of point-of-care diagnostics, demand for faster turnaround times, integration of molecular diagnostics, rising infectious disease awareness. Major trends in the forecast period include rising use of multiplex molecular diagnostic panels, increased demand for rapid stool testing, expansion of point-of-care gi diagnostics, growing adoption of pcr-based testing, enhanced focus on infection surveillance.

The increasing occurrence of foodborne diseases is expected to drive the growth of the gastrointestinal pathogen testing market in the coming years. Foodborne diseases are illnesses caused by consuming food or beverages contaminated with pathogenic microorganisms, toxins, or chemical substances. These diseases include listeriosis, viral gastroenteritis, taeniasis, and trichinosis. The rise in foodborne incidents is attributed to factors such as changes in food production, distribution, and consumption patterns, inadequate food safety measures, and the impact of climate change on food production. Gastrointestinal pathogen testing helps identify the specific pathogens responsible for foodborne illnesses, enabling healthcare providers to determine the cause of gastrointestinal symptoms, select appropriate treatments, track outbreaks, and implement preventive measures to limit disease spread. For example, in September 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported that during 2023, it, along with state and regulatory public health partners, investigated 181 potential multistate outbreaks, of which 84 were confirmed as outbreaks. Of these, investigators resolved 50 outbreaks (60%), identified a suspected source for 22 outbreaks, and confirmed a source for 28 outbreaks. Thus, the rising incidence of foodborne diseases is driving the gastrointestinal pathogen testing market.

The growing issue of antimicrobial resistance is also expected to fuel the expansion of the gastrointestinal pathogen testing market. Antimicrobial resistance refers to the ability of bacteria, viruses, and other microorganisms to survive treatments that were previously effective against them. The demand for gastrointestinal pathogen testing is increasing due to the rising prevalence of drug-resistant gastrointestinal infections, which require rapid and accurate detection to guide effective treatment and prevent further transmission. For instance, in October 2025, the World Health Organization (WHO), a Switzerland-based specialized UN agency, reported a global analysis of antibiotic resistance prevalence and trends, based on over 23 million bacteriologically confirmed cases of bloodstream infections, urinary tract infections, gastrointestinal infections, and urogenital gonorrhea, with data contributed by 104 countries in 2023. Therefore, increasing antimicrobial resistance is expected to drive growth in the gastrointestinal pathogen testing market.

Key players in the gastrointestinal pathogen testing market are focusing on developing advanced solutions, such as metagenomic diagnostic tests, to improve the speed, accuracy, and comprehensiveness of pathogen detection. Metagenomic diagnostic testing is an advanced method that analyzes the genetic material of microorganisms present in a sample, such as stool or blood. For example, in April 2024, Microba Life Sciences, an Australia-based biotechnology company, launched MetaPanel, a metagenomic diagnostic test designed to identify a broad range of gastrointestinal pathogens with exceptional accuracy. MetaPanel targets 175 pathogens in a single test, providing healthcare professionals with a comprehensive solution for diagnosing both common and hard-to-detect infections. It uses next-generation sequencing (NGS) technology to analyze the genetic material in a stool sample, enabling detection of pathogens not routinely included in traditional gastrointestinal panels.

Major companies operating in the gastrointestinal pathogen testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton Dickinson and Company, Hologic Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Cepheid Inc., OraSure Technologies Inc., BioFire Diagnostics Inc., Luminex Corporation, Meridian Bioscience Inc., Sekisui Diagnostics LLC, ELITechGroup S.A.S., Hardy Diagnostics LLC, Trinity Biotech plc, R-Biopharm AG, COPAN Diagnostics Inc., Savyon Diagnostics Ltd., ZeptoMetrix Corporation, Biomerica Inc., Pro-Lab Diagnostics.

North America was the largest region in the gastrointestinal pathogen testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal pathogen testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastrointestinal pathogen testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastrointestinal pathogen testing market by increasing costs of imported diagnostic kits, reagents, and molecular testing instruments. Diagnostic laboratories and hospitals are most affected due to reliance on imported technologies. These tariffs raise testing costs by increasing consumable and equipment expenses, potentially limiting routine pathogen screening. However, they promote domestic production of diagnostic solutions, improving regional testing capacity and supply resilience.

The gastrointestinal pathogen testing market research report is one of a series of new reports that provides gastrointestinal pathogen testing market statistics, including gastrointestinal pathogen testing industry global market size, regional shares, competitors with a gastrointestinal pathogen testing market share, detailed gastrointestinal pathogen testing market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal pathogen testing industry. This gastrointestinal pathogen testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal pathogen testing involves diagnosing infections and diseases caused by various pathogens affecting the digestive tract, including the stomach and intestines. It includes analyzing specimens, such as stool or blood, to identify the specific pathogens responsible for gastrointestinal symptoms, enabling accurate diagnosis and treatment of gastrointestinal disorders.

The main types of pathogens detected in gastrointestinal pathogen testing include bacteria, viruses, and parasites. Bacteria are microscopic organisms that can lead to illness in the digestive system. The testing methods include molecular tests, culture, biochemical tests, and others, with different panel types, such as syndromic full multiplex panels, among others. These tests are utilized by various end-users, including hospitals, diagnostic laboratories, point-of-care settings, and others.

The gastrointestinal pathogen testing market consists of revenues earned by entities by providing services, such as molecular testing, culture and sensitivity testing, and rapid diagnostics tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal pathogen testing market also includes sales of testing kits, laboratory equipment, and PCR (Polymerase Chain Reaction) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.